Patents Examined by Taylor V. Oh
  • Patent number: 10745373
    Abstract: The present invention relates to a process for preparing fluorescein quinoid form of Formula (I): Furthermore, the present invention relates to a new solid fluorescein form and a process for the preparation thereof. The present invention also relates to the use of said new solid fluorescein form in the synthesis of fluorescein quinoid form.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: August 18, 2020
    Assignee: Delmar Chemicals Inc.
    Inventors: Nicolas Tesson, Eduard Bugan, Nadejda Spassova, Alain Menard
  • Patent number: 10744087
    Abstract: Disclosed herein are methods, formulations, and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using selective ?1 adrenergic receptor blockers. Also disclosed herein are methods, formulations, and kits for treating a heart condition via inhalation or intranasal spray administration of selective ?1 adrenergic receptor blocker and class I antiarrhythmic agent.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: August 18, 2020
    Assignee: InCarda Therapeutics, Inc.
    Inventors: Luiz Belardinelli, Rangachari Narasimhan, Carlos Schuler
  • Patent number: 10738022
    Abstract: Provided are processes for monitoring and maintaining continuous carbonylation of epoxides or lactones. Processes include measuring parameters affecting the rate of the carbonylation reaction and adding supplemental replacement catalyst replacement components to maintain a constant rate of carbonylation.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: August 11, 2020
    Assignee: Novomer, Inc.
    Inventors: Jay J. Farmer, Peter Galebach, Kyle Sherry, Sadesh H. Sookraj
  • Patent number: 10738023
    Abstract: Provided is a method for producing a 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, which is suitable for the production on an industrial scale. The present invention provides: a method for producing an intermediate for the production of a 2-alkylcarbonyl[2,3-b]furan-4,9-dione, which comprises reacting a 1-butyne derivative in which a ketone or an alcohol is protected with a 2-hydroxy-1,4-naphthoquinone derivative having a leaving group at position-3 in a solvent in the presence of a metal or a metal compound and a base; and a substance relating to the intermediate.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: August 11, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Kazuhiko Takahashi, Shoji Watanabe, Katsuya Uchiyama, Kento Senami
  • Patent number: 10738044
    Abstract: {4-[3-(Dimethylamino)propoxy]phenyl}methyl (4S)-4-(propan-2-yl)-3H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carboxylate, and pharmaceutically or veterinarily acceptable salts thereof.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: August 11, 2020
    Assignee: PROXIMAGEN, LLC
    Inventor: Lee Patient
  • Patent number: 10723712
    Abstract: Disclosed is a process to produce a purified vapor comprising dialkyl-furan-2,5-dicarboxylate (DAFD). Furan-2,5-dicarboxylic acid (FDCA) and an alcohol in an esterification zone to generate a crude diester stream containing dialkyl furan dicarboxylate (DAFD), unreacted alcohol, 5-(alkoxycarbonyl)furan-2-carboxylic acid (ACFC), and alkyl furan-2-carboxylate (AFC). The esterification zone comprises at least one reactor that has been previously used in an DMT process.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: July 28, 2020
    Assignee: Eastman Chemical Company
    Inventors: Kevin John Fontenot, Mesfin Ejerssa Janka, Kenny Randolph Parker, Ashfaq Shahanawaz Shaikh
  • Patent number: 10723718
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a triazole-methyl-piperidinyl-pyrolyl-propenone structure which function as modulators of shared epitope (SE)-calreticulin (CRT) binding and/or interaction, and their use as therapeutics for the treatment of immunoregulatory abnormalities (e.g., autoimmune diseases, inflammatory diseases (e.g., chronic inflammatory disease), and bone erosive diseases) by selectively inhibiting SE-CRT interactions and/or signal transduction pathways commonly overactive or dysregulated in arthritic and/or other diseases or conditions.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: July 28, 2020
    Assignee: The Regents of the University of Michigan
    Inventors: Joseph Holoshitz, Andrew White
  • Patent number: 10723748
    Abstract: The present invention relates to novel monomaleimide-functionalized platinum compounds of formula (I), including in particular novel monomaleimide-functionalized oxaliplatin and carboplatin derivatives, as well as their use as medicaments, particularly for the treatment or prevention of cancer.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 28, 2020
    Assignees: Medizinische Universität Wien, Universität Wien
    Inventors: Christian Kowol, Petra Heffeter, Walter Berger, Bernhard K. Keppler, Josef Mayr, Verena Pichler
  • Patent number: 10717719
    Abstract: Processes for producing ethylene carbonate and/or ethylene glycol, and associated reaction systems are similarly provided. Specifically, a process is provided that comprises supplying an overhead absorber stream withdrawn from an absorber to a vapor-liquid separator to yield an aqueous bottoms stream and a recycle gas stream; supplying an aqueous process stream comprising one or more impurities to a distillation apparatus to yield an overhead impurities stream and a purified aqueous process stream; supplying at least a portion of the purified aqueous process stream and an ethylene oxide product stream to the absorber; and contacting the ethylene oxide product stream with the purified aqueous process stream in the absorber in the presence of one or more carboxylation and hydrolysis catalysts to yield a fat absorbent stream comprising ethylene carbonate and/or ethylene glycol.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: July 21, 2020
    Assignee: Shell Oil Company
    Inventors: Jesse Raymond Black, Roel Guillaume Hubertus Leonardus Bastings, Alexandre Molina
  • Patent number: 10710970
    Abstract: The present disclosure provides methods to produce 5-(halomethyl)furfural, including 5-(chloromethyl)furfural, by acid-catalyzed conversion of C6 saccharides, including isomers thereof, polymers thereof, and certain derivatives thereof. The methods make use of acids with lower concentrations, and allows for conversion of sugars into 5-(halomethyl)furfural at higher temperatures and faster reaction or residence times.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: July 14, 2020
    Assignee: MICROMIDAS, INC.
    Inventors: Alex B. Wood, Makoto N. Masuno, Ryan L. Smith, John Bissell, Dimitri A. Hirsch-Weil, Robert Joseph Araiza, Daniel R. Henton, James H. Plonka
  • Patent number: 10711003
    Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: July 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Liqi He, Sanjeev Gangwar, Shoshana L. Posy, Yam B. Poudel, Prasanna Sivaprakasam
  • Patent number: 10703747
    Abstract: This invention is benzothiophene-based selective mixed estrogen receptor downregulators and their compositions and uses to treat estrogen-related disorders.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: July 7, 2020
    Assignee: The Board of Directors of the University of Illinois
    Inventors: Gregory R. Thatcher, Rui Xiong, Yunlong Lu, Jiong Zhao, Debra A. Tonetti
  • Patent number: 10703741
    Abstract: The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: July 7, 2020
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Edward Jean Beaumont, Rajesh Devraj, Philip Stephen Kerry, Gnanasambandam Kumaravel, Pui Leng Loke, Mirco Meniconi, Jordan John Palfrey, Carl North, Cristina Lecci, Heather Tye
  • Patent number: 10702506
    Abstract: Provided herein are small molecule inhibitors of pendrin. More specifically, the small molecules disclosed herein may be used to inhibit pendrin-mediated anion exchange. These small molecules may be used for treatment of diseases and disorders that are treatable by inhibiting pendrin, such as cystic fibrosis, rhinitis, chronic rhinosinusitis, exposure to an industrial toxin, certain viral infections, certain bacterial infections, and chronic obstructive pulmonary disease. The small molecules may further be used to potentiate a diuretic effect of a diuretic compound. The small molecules may additionally be used to treat hypertension or thyroid conditions.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 7, 2020
    Assignee: The Regents of the University of California
    Inventors: Alan S. Verkman, Peter M. Haggie, Onur Cil
  • Patent number: 10696703
    Abstract: Provided are: eushearilides; a method for producing eushearilides; a production intermediate; and a pharmaceutical composition containing eushearilides. By having the Wittig reaction process, Mukaiyama Aldol reaction process and Macrolactonizaion process serve as key processes, eushearilides represented by formula (I) are efficiently produced.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 30, 2020
    Assignee: TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Isamu Shiina, Takayuki Tonoi
  • Patent number: 10696663
    Abstract: The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 30, 2020
    Assignee: Artax Biopharma Inc.
    Inventors: Julio Castro, Andrés Gagete Mateos, Peter J. Machin, Christopher Loren VanDeusen
  • Patent number: 10688062
    Abstract: The present invention provides compositions useful in reducing or preventing pain in a subject in need thereof. In one embodiment, the compositions comprise a halogenated volatile compound. The present invention further includes a method of reducing or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of the invention. Dosing regimens contemplated within the invention include one-time administration, continuous administration or periodic administration.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: June 23, 2020
    Assignee: Vapogenix, Inc.
    Inventors: Danguole Spakevicius, Heather Giles, Terry Farmer
  • Patent number: 10682323
    Abstract: Provided is a novel therapeutic agent for glaucoma, which has sGC-activating action. A therapeutic agent for glaucoma or an ocular hypotensive agent, which contains, as an effective component, a compound represented by Formula (I-a) or Formula (I-b) and having a Log D value of more than 1.5 and less than 2.5, or a pharmaceutically acceptable salt thereof. [In formulae (I-a) and (I-b), each symbol is as defined in the description.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: June 16, 2020
    Assignee: TOA EIYO LTD.
    Inventors: Toshihiro Sawabe, Fumito Maruyama, Akiyuki Takaya, Takeshi Hasegawa
  • Patent number: 10686145
    Abstract: Disclosed are an organic compound selected from a compound represented by Chemical Formula 1A, a compound represented by Chemical Formula 1B, and a combination thereof, an organic thin film including the organic compound, an organic thin film transistor, and an electronic device. The organic compound has liquid crystal properties and exhibits an ordered liquid crystal phase when being heated in a liquid crystal period due to asymmetric substituents and thereby charge mobility may be further improved.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: June 16, 2020
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Eun Kyung Lee, Jeong Il Park, Don-Wook Lee
  • Patent number: 10676458
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: June 9, 2020
    Assignee: Merch Sharp & Dohne Corp. Rahway
    Inventors: Michael Miller, Harry R. Chobanian